Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting (2009)

Author(s): Minto CLJ; Case MC; Irving JAE; Lawson S; Jesson J; Virgo P; Eyre L; Noel N; Johansson U; Macey M; Knotts L; Helliwell M; Davies P; Whitby L; Barnett D; Hancock J; Goulden N

    Abstract: Minimal residual disease detection, used for clinical management of children with acute lymphoblastic leukemia, can be performed by molecular analysis of antigen-receptor gene rearrangements or by flow cytometric analysis of aberrant immunophenotypes. For flow minimal residual disease to be incorporated into larger national and international trials, a quality assured, standardized method is needed which can be performed in a multi-center setting. We report a four color, flow cytometric protocol established and validated by the UK acute lymphoblastic leukemia Flow minimal residual disease group. Quality assurance testing gave high inter-laboratory agreement with no values differing from a median consensus value by more than one point on a logarithmic scale. Prospective screening of B-ALL patients (n=206) showed the method was applicable to 88.3% of patients. The minimal residual disease in bone marrow aspirates was quantified and compared to molecular data. The combined risk category concordance (minimal residual disease levels above or below 0.01%) was 86% (n=134). Thus, this standardized protocol is highly reproducible between laboratories, sensitive, applicable, and shows good concordance with molecular-based analysis.

    • Type of Article: Brief Report
    • Journal: Haematologica
    • Volume: 94
    • Issue: 6
    • Pages: 870-874
    • Publisher: Fondazione Ferrata Storti
    • Publication type: Article
    • Bibliographic status: Published

    Keywords: childhood acute lymphoblastic leukemia minimal residual disease flow cytometry


    Dr Julie Irving
    Reader in Experimental Haematology